Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB03-154 as Adjunctive Therapy in Focal Epilepsy
NCT06612775Phase 2Recruiting
- Sponsor
- Zhimeng Biopharma
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CB03-154 in focal epilepsy (4 arms), sponsored by Zhimeng Biopharma. Primary endpoints: Focal Seizure Frequency at 20 weeks and Adverse Events at 17 weeks. Started Aug 2024; status: recruiting.
02
Drugs
CB03-154
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT06612775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612775.